Skip to main content
AAN.com
Articles
February 1, 2002

Levodopa strengths and weaknesses

February 1, 2002 issue
58 (suppl_1) S19-S32

Abstract

Despite clinical experience with levodopa for more than three decades, the role of this agent in the treatment of Parkinson’s disease (PD) has not been well defined. Clearly the most effective antiparkinsonian drug, levodopa, is associated with emergence of motor complications, particularly fluctuations and dyskinesias, as well as other side effects. In addition to these limitations, there is an ongoing debate about the potential neurotoxic effects of levodopa, suggested by some in vitro studies. However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Jankovic J. Complications and limitations of drug therapy for movement disorders. Neurology . 2000; 55 (suppl 6): S2–6.
2.
Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology . 2001; 56 (suppl 5): S1–88.
3.
Jankovic J. Parkinson’s disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol . 2000; 23: 252–261.
4.
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol . 1984; 7: 35–49.
5.
Männistö PT, Kaakola S. Rationale for selective COMT inhibitors as adjuvants in the drug treatment of Parkinson’s disease. Pharmacol Toxicol . 1990; 66: 317–323.
6.
Opacka-Juffrey J, Brooks DJ. L-dihydroxyphenylalanine and its decarboxylase: new ideas on the neuroregulatory roles. Mov Disord . 1995; 10: 241–249.
7.
Cedarbaum JM, Kutt H, Dhar AK, et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol . 1986; 9: 153–159.
8.
Apaydin H, Ertan S, Özekmerci S. Broad bean (Vicia faba)—a natural source of L-dopa—prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations. Mov Disord . 2000; 15: 164–166.
9.
Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol . 1992; 49: 149–151.
10.
Fahn S. Parkinson’s disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol . 1999; 56: 529–535.
11.
Weiner WJ. The initial treatment of Parkinson’s disease should begin with levodopa. Mov Disord . 1999; 14: 716–724.
12.
Montastruc JL, Rascol O, Senard J-M. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord . 1999; 14: 725–730.
13.
Helmuth L. Researcher overlooked for 2000 Nobel. Science . 2001; 291: 567–568.
14.
Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Dis . 1998; 4: 53–57.
15.
Birkmayer W, Hornykiewicz O. The effect of L-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Dis . 1998; 4: 59–60.
16.
Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med . 1967; 276: 374–379.
17.
Jankovic J, Kapadia AS. Functional decline in Parkinson’s disease. Arch Neurol . 2001; 58: 1611–1615.
18.
Louis ED, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson’s disease. Arch Neurol . 1999; 56: 334–337.
19.
Klawans HL. Individual manifestations of Parkinson’s disease after ten or more years of levodopa. Mov Disord . 1986; 1: 187–192.
20.
Fahn S. Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs . 1997; 8: 376–393.
21.
Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol . 1998; 43: 551–554.
22.
Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson’s disease. Can J Neurol Sci . 1992; 19: 108–112a.
23.
Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci . 1999; 64: 1275–1285.
24.
Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord . 1997; 12: 634–638.
25.
Agid Y. Levodopa: is toxicity a myth? Neurology . 1998; 50: 858–863.
26.
Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci . 1996; 16: 2553–2562.
27.
Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurons in culture from L-dopa toxicity. Neuroreport . 1996; 7: 441–445.
28.
Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol . 1998; 43: 561–575.
29.
Datla KP, Blunt SB, Dexter DT. Chronic L-dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostrial lesions. Mov Disord . 2001; 16: 424–434.
30.
Okazawa H, Murata M, Watanabe M, et al. Dopaminergic stimulation upregulates in vivo expression of brain derived neurotrophic factor (BDNF) in the striatum. FEBS Lett . 1992; 313: 138–142.
31.
Han SK, Mytilineou C, Cohen G. L-dopa upregulated glutathione and protects mesencephalic structures against oxidative stress. J Neurochem . 1996; 66: 501–510.
32.
Caraceni T. A case for early levodopa treatment of Parkinson’s disease. Clin Neuropharmacol . 1994; 17: S38–42.
33.
Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease. Neurology . 1993; 43: 1918–1926.
34.
Gwinn-Hardy K, Evidente VG, Waters C, Muenter MD, Hardy J. L-dopa slows the progression of familial parkinsonism. Lancet . 1999; 353: 1850–1851.
35.
Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord . 1995; 10: 250–256.
36.
Shuman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality practice patterns should change. Arch Neurol . 2000; 57: 406–410.
37.
Weiner WJ. Is levodopa toxic? Arch Neurol . 2000; 57: 408–409.
38.
Verhagen Metman L, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson’s disease: hypotheses on the why, where, and what. Mov Disord . 2000; 15: 3–8.
39.
Obeso JA, Rodriguez-Oroz MAC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol . 2000; 47 (suppl 1): S22–34.
40.
Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trends Neurosci . 2000; 23 (suppl 10): S2–7.
41.
Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN. Levodopa, melanoma, and Parkinson’s disease. Neurology . 1993; 43: 674–677.
42.
Woofer MJA, Manyan BV. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol . 1994; 17: 315–319.
43.
Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol . 1997; 37: 332–336.
44.
Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs . 1996; 52: 773–794.
45.
Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med . 1993; 95: 38–48.
46.
Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA . 1997; 277: 1046–1051.
47.
Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (suppl 1): S2–11.
48.
Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord . 1992; 7: 117–124.
49.
Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson’s disease. Neurology . 1993; 43: 1459–1464.
50.
Vidailhet M, Bonnet AM, Marconi N. The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord . 1999; 14 (suppl 1): 13–18.
51.
Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD. Implications for wearing off. Neurology . 1999; 52: 763–767.
52.
Vidailhet M, Bonnet AM, Marconi N, et al. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology . 1994; 44: 1613–1616.
53.
Marconi R, Lefebvre-Caparros D, Bonnet A-M, et al. Levodopa-induced dyskinesia in Parkinson’s disease: phenomenology and pathophysiology. Mov Disord . 1994; 9: 2–12.
54.
Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain . 1991; 114: 2283–2301.
55.
Jankovic J, Nour F. Respiratory dyskinesia in Parkinson’s disease. Neurology . 1986; 36: 303–304.
56.
Rascol O. L-dopa-induced peak-dose dyskinesias in patients with Parkinson’s disease: a clinical pharmacologic approach. Mov Disord . 1999; 14 (suppl 1): 19–32.
57.
Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord . 1999; 14: 836–838.
58.
Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord . 2001; 8: 109–121.
59.
Schrag AS, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain . 2000; 123: 2297–2305.
60.
Jankovic J, Marsden CD. Therapeutic strategies in Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders. 3rd ed. Baltimore: Williams & Wilkins, 1998: 191–220.
61.
Olanow CW, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci . 2000; 23 (suppl 10): S117–126.
62.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord . 2001; 16: 448–458.
63.
Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol . 1996; 39: 37–45.
64.
Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology . 1986; 36: 1528–1530.
65.
Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. Eur Neurol . 1997; 37: 23–27.
66.
Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol . 1997; 42: 349–355.
67.
Jankovic J, Linfante I, Dawson LE, Contant C. Young-onset versus late-onset Parkinson’s disease: clinical features and disease progression. Ann Neurol . 1997; 42: 448.
68.
Quinn NP, Critchely P, Marsden CD. Young-onset parkinsonism. Mov Disord . 1987; 2: 73–91.
69.
Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson’s disease. Neurology . 1990; 40: 927–933.
70.
Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson’s disease: contribution of postsynaptic mechanisms. Ann Neurol . 1994; 36: 27–31.
71.
Luquin MR, Laguna J, Obeso JA. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol . 1992; 31: 551–554.
72.
Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology . 1999; 53: 1425–1430.
73.
Verhagen Metman L, van den Munckhof, Klaassen AAG, et al. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson’s disease. Neurology . 1997; 49: 711–713.
74.
Zappia M, Oliveri RL, Bosco D, et al. The long-duration response to L-dopa in the treatment of early PD. Neurology . 2000; 54: 1910–1915.
75.
Nutt JG. Response to L-dopa in PD. The long and short of it. Neurology . 2000; 54: 1884–1885.
76.
Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson’s disease. Mayo Clin Proc . 1999; 74: 1239–1254.
77.
Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology . 1991; 41: 630–633.
78.
Sage JI, Mark MH. The rationale for continuous dopaminergic stimulation in patients with Parkinson’s disease. Neurology . 1992; 42 (suppl 1): S23–28.
79.
Hammerstad JP, Woodward WR, Nutt JG, et al. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol . 1994; 17: 429–434.
80.
Koller WC, Hutton JT, Tolosa E, Capilldeo R, and the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD. Neurology . 1999; 53: 1012–1019.
81.
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology . 1998; 51: 1309–1314.
82.
Holm KJ, Spencer CM. Entacapone. A review of its use in Parkinson’s disease. Drugs . 1999; 58: 159–177.
83.
Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson’s disease. Neurology . 1998; 50 (suppl 5): S3–14.
84.
The Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord . 1999; 14: 38–44.
85.
Ruottine HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol . 1998; 245 (suppl 3): 25–34.
86.
Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry . 1994; 57: 186–189.
87.
Kurth MC, Adler CH, St Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology . 1997; 48: 81–87.
88.
Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry . 2000; 68: 589–594.
89.
Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA . 1997; 278: 125–130.
90.
Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology . 1997; 49: 665–671.
91.
Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet . 1998; 352: 958.
92.
Haasio K, Sopanen L, Vaalavirta L, et al. Comparative toxicological study in the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm . 2001; 108: 79–91.
93.
Cedarbaum JM, Olanow CW. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson’s disease. Neurology . 1991; 41: 1567–1570.
94.
Colosimo C, Merello M, Hughes A, et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson’s disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry . 1996; 61: 634–637.
95.
Leenders KL, Poweve WH, Palmer AJ, et al. Inhibition of [18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol . 1986; 20: 258–262.
96.
De la Fuente-Fernandez R, Lu J-QL, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol . 2001; 49: 298–303.
97.
Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res . 1994; 662: 69–74.
98.
Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias. Neurology . 1997; 49: 717–723.
99.
Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson’s disease and the pathogenesis of motor complications. Neurology . 1997; 48: 369–372.
100.
Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to L-dopa in fluctuating PD. Neurology . 2000; 54: 247–250.
101.
Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol . 1996; 39: 574–578.
102.
Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson’s disease. Mov Disord . 1996; 11: 580–581.
103.
Verhagen Metman L, Dotto PD, LePoole K, et al. Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study. Arch Neurol . 1999; 56: 1383–1386.
104.
Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology . 1998; 50: 1323–1326.
105.
Pearce RKB, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord . 1995; 10: 731–740.
106.
Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of L-dopa-induced dyskinesias. Mov Disord . 1999; 14 (suppl 1): 4–8.
107.
Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (suppl 1): S70–78.
108.
Canales JJ, Graybiel AM. Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol . 2000; 47 (suppl 1): S53–59.
109.
Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol . 2000; 47 (suppl 1): S90–104.
110.
Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res . 1991; 547: 152–161.
111.
Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol . 1996; 40: 355–366.
112.
Lang AE, Lozano A, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson’s disease. N Engl J Med . 1997; 337: 1036–1042.
113.
Jankovic J, Lai E, Krauss JK, Grossman RG. Surgical treatment of levodopa-induced dyskinesias. In: Stern G, ed. Parkinson’s Disease. Advances in Neurology, vol 80. Philadelphia: Lippincott Williams & Wilkins, 1999: 603–610.
114.
Uitti RJ, Wharen RE, Turk MF, et al. Unilateral pallidotomy for Parkinson’s disease: comparison of outcome in younger versus elderly patients. Neurology . 1997; 49: 1072–1077.
115.
Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol . 1999; 46: 732–738.
116.
Boraud T, Bezard E, Bioulac B, Gross CE. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurons in the MPTP-treated monkey. Brain . 2001; 124: 546–557.
117.
Lang AE. Surgery for levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (suppl 1): S193–202.
118.
Rascol O, Sabatini U, Brefel C, et al. Cortical and motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain . 1998; 121: 527–533.
119.
Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (suppl 1): S179–188.
120.
Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology . 1997; 48: 1077–1081.
121.
Bonucceli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology . 1997; 49: 1587–1590.
122.
Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord . 2000; 15: 201–211.
123.
Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord . 1994; 9: 409–414.
124.
Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology . 1995; 45: 1855–1858.
125.
Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson’s disease. Neurology . 1996; 46: 1548–1551.
126.
Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson’s disease: clinical and pharmacologic features. Ann Neurol . 1988; 23: 73–78.
127.
Jankovic J, Brin M. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve . 1997; 20 (suppl 6): S129–145.
128.
Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain . 2000; 123: 733–745.
129.
Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry . 2000; 68: 423–428.
130.
Lang AE. Akathisia and the restless legs syndrome. In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders, 2nd ed. Baltimore: Williams and Wilkins, 1993: 399–418.
131.
Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disord . 1992; 7: 125–131.
132.
Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med . 1999; 340: 757–763.
133.
Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology . 1995; 45: 432–434.
134.
Scelsa SN, Simpson DM, McQuistion HL, Fineman A, Ault K, Reichler B. Clozapine-induced myotoxocity in patients with chronic psychotic disorders. Neurology . 1996; 47: 1518–1523.
135.
Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, 5-HT3 receptor antagonist. Neurology . 1995; 45: 1305–1308.
136.
Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology . 1996; 47: 1085–1087.
137.
Graham JM, Kay JD, Ford K, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson’s disease: a cautionary note. J Neurol Neurosurg Psychiatry . 1998; 65: 774–777.
138.
Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology . 2000; 55: 795–799.
139.
Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced by hallucinations. Mov Disord . 2000; 15 (Suppl 3): 127.
140.
Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord . 1999; 14: 484–487.
141.
Kurlan R, Tanner CM, Goetz C, et al. Levodopa drug holiday versus drug dosage reduction in Parkinson’s disease. Clin Neuropharmacol . 1994; 17: 117–127.
142.
Nutt JG, Carter JH, Woodward WR. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology . 1994; 44: 1617–1622.
143.
Corona T, Rivera C, Otero E, Stopp L. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson’s disease. Clin Neuropharmacol . 1995; 18: 325–332.
144.
Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease. Neurology . 1999; 52: 777–781.
145.
Currie LJ, Bennett JP, Harrison MB, et al. Clinical correlates of sleep benefit in Parkinson’s disease. Neurology . 1997; 48: 1115–1117.
146.
Högl BE, Gómez-Arévalo G, García S, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson’s disease. Neurology . 1998; 50: 1323–1339.

Information & Authors

Information

Published In

Neurology®
Volume 58Number suppl_1February 1, 2002
Pages: S19-S32
PubMed: 11909982

Publication History

Published online: February 1, 2002
Published in print: February 1, 2002

Authors

Affiliations & Disclosures

Joseph Jankovic, MD
From the Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX.

Notes

Address correspondence and reprint requests to Dr. Joseph Jankovic, Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Effects of Tiliroside and Lisuride Co-Treatment on the PI3K/Akt Signal Pathway: Modulating Neuroinflammation and Apoptosis in Parkinson’s Disease, Biomedicines, 11, 10, (2735), (2023).https://doi.org/10.3390/biomedicines11102735
    Crossref
  2. Neuroimaging and serum biomarkers of neurodegeneration and neuroplasticity in Parkinson’s disease patients treated by intermittent theta-burst stimulation over the bilateral primary motor area: a randomized, double-blind, sham-controlled, crossover trial study, Frontiers in Aging Neuroscience, 15, (2023).https://doi.org/10.3389/fnagi.2023.1258315
    Crossref
  3. Therapeutic potential of lipid nanosystems for the treatment of Parkinson’s disease, Ageing Research Reviews, 89, (101965), (2023).https://doi.org/10.1016/j.arr.2023.101965
    Crossref
  4. Surveying Global Availability of Parkinson’s Disease Treatment, Journal of Parkinson's Disease, 12, 3, (1023-1034), (2022).https://doi.org/10.3233/JPD-213006
    Crossref
  5. DAT and TH expression marks human Parkinson’s disease in peripheral immune cells, npj Parkinson's Disease, 8, 1, (2022).https://doi.org/10.1038/s41531-022-00333-8
    Crossref
  6. The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study, Journal of the Neurological Sciences, 437, (120263), (2022).https://doi.org/10.1016/j.jns.2022.120263
    Crossref
  7. Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications, Pharmaceutics, 13, 9, (1395), (2021).https://doi.org/10.3390/pharmaceutics13091395
    Crossref
  8. Novel targeted therapies for Parkinson’s disease, Molecular Medicine, 27, 1, (2021).https://doi.org/10.1186/s10020-021-00279-2
    Crossref
  9. Analyzing Head Pose in Remotely Collected Videos of People with Parkinson’s Disease, ACM Transactions on Computing for Healthcare, 2, 4, (1-13), (2021).https://doi.org/10.1145/3459669
    Crossref
  10. An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease, Expert Opinion on Pharmacotherapy, 22, 8, (965-972), (2021).https://doi.org/10.1080/14656566.2021.1895748
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share